Madrigal Pharmaceuticals, Inc. (MDGL) income statement
MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/306% below fair value
$379.10−17.64 (-4.45%)
Close on Nov 20, 2026Market cap $8.76BP/E –Yield –
Madrigal Pharmaceuticals, Inc. financial ratios
See a number that looks wrong?